- Record: found
- Abstract: not found
- Article: not found
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR +/HER2 − Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)
Aditya Bardia ,
Sara A. Hurvitz ,
Angela DeMichele ,
Amy S. Clark ,
Amelia Zelnak ,
Denise A. Yardley ,
Meghan Karuturi ,
Tara Sanft ,
Sibel Blau ,
Lowell Hart ,
Cynthia Ma ,
Hope S. Rugo ,
Das Purkayastha ,
Stacy Moulder
August 02 2021
March 15 2021
Read this article at
ScienceOpenPublisherPMC
- open (via free pdf)
- oa repository (via pmcid lookup)
- oa repository (via page says license)
- oa repository (via OAI-PMH title and first author match)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
Powered by 
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d3281004e253">Standard-of-care treatment for metastatic hormone
receptor-positive (HR+), HER2-negative
(HER2-) breast cancer includes endocrine therapy (ET) combined with a cyclin-dependent
kinase 4/6 inhibitor (CDK4/6i). Optimal treatment after progression on CDK4/6i is
unknown. The TRINITI-1 trial investigated ribociclib, a CDK4/6i that has recently
demonstrated significant overall survival benefit in two phase III trials, in combination
with everolimus and exemestane in patients with HR+, HER2- advanced breast cancer
(ABC) after progression on a CDK4/6i.
</p>